Skip to content

Antineoplastic drug

Inproquone (INN)

CAS 436-40-8
8

Safety score · 0–100

Avoid

Derived from EU CosIng regulatory status, PubChem hazard data and published research. How we score.

An investigational chemotherapy agent from the DNA-alkylating aziridinyl quinone family. It is a pharmaceutical, not a cosmetic ingredient, and is unsuitable for use on skin in any consumer product.

Skin benefits

  • Investigational aziridinyl quinone antitumor agent
  • Historically explored as an experimental cytotoxic drug
  • Studied in the context of DNA cross-linking chemotherapy research

Known concerns

  • Aziridinyl quinones alkylate DNA and form interstrand cross-links (genotoxic mechanism)
  • Class associated with carcinogenic and mutagenic potential
  • Not approved or appropriate for use in cosmetic products
  • Active pharmaceutical drug class, not a topical skin ingredient
  • EU bans CMR substances of categories 1A, 1B, and most category 2 from cosmetics

References

EU

EU CosIng database

European Commission cosmetic ingredient registry: regulatory status, restrictions, authorised functions.

Check your shelf

Find Inproquone (INN) in your products.

Scan any cosmetic product with LuxSense to see if it contains Inproquone (INN) and get a full ingredient breakdown with safety scores.

This profile is for educational purposes and does not constitute medical advice. Regulatory status and scientific understanding evolve, so always read the physical product label and consult a healthcare professional for personal concerns.